Differential Regulation of Cellular Tropism and Sensitivity to Soluble CD4 Neutralization by the Envelope Gp120 of Human Immunodeficiency Virus Type 1

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1994 Aug 1

PMID 8035496

Citations 14

Authors

L Stamatatos

A Werner

C Cheng-Mayer

Affiliations

Soon will be listed here.

Abstract

Using recombinant and mutant viruses generated between two human immunodeficiency virus type 1 isolates that display differences in cell tropism and sensitivity to soluble CD4 neutralization, we show that these two properties of the virus are regulated by different mechanisms. Whereas there is an association between V3 loop conformation and a particular cellular tropism, soluble CD4 neutralization sensitivity appears to be determined by amino acid differences in the C2 domain of the envelope gp120 that modulate the stability of gp120-gp41 association. Our findings further illustrate the importance of functional interactions among different regions of the envelope gp120 in regulating the biological phenotypes of human immunodeficiency virus and suggest that additional probing of the V3 loop with monoclonal antibodies may identify specific structural features of this loop that determine cell tropism.

Citing Articles

Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.

Zhuang K, Finzi A, Toma J, Frantzell A, Huang W, Sodroski J Retrovirology. 2012; 9:106.

PMID: 23237529 PMC: 3528637. DOI: 10.1186/1742-4690-9-106.

Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination.

Du T, Hu K, Yang J, Jin J, Li C, Stieh D Antimicrob Agents Chemother. 2012; 56(9):4640-9.

PMID: 22687513 PMC: 3421874. DOI: 10.1128/AAC.00623-12.

Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

White T, Bartesaghi A, Borgnia M, de la Cruz M, Nandwani R, Hoxie J J Virol. 2011; 85(23):12114-23.

PMID: 21937655 PMC: 3209358. DOI: 10.1128/JVI.05297-11.

Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide.

Cheng-Mayer C, Huang Y, Gettie A, Tsai L, Ren W, Shakirzyanova M AIDS. 2011; 25(15):1833-41.

PMID: 21750420 PMC: 3508694. DOI: 10.1097/QAD.0b013e32834a1d94.

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Labrijn A, Poignard P, Raja A, Zwick M, Delgado K, Franti M J Virol. 2003; 77(19):10557-65.

PMID: 12970440 PMC: 228502. DOI: 10.1128/jvi.77.19.10557-10565.2003.

References

OBRIEN W, Chen I, Ho D, Daar E . Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol. 1992; 66(5):3125-30. PMC: 241075. DOI: 10.1128/JVI.66.5.3125-3130.1992. View

Hwang S, Boyle T, Lyerly H, Cullen B . Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science. 1992; 257(5069):535-7. DOI: 10.1126/science.1636088. View

Chesebro B, Wehrly K, Nishio J, Perryman S . Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol. 1992; 66(11):6547-54. PMC: 240149. DOI: 10.1128/JVI.66.11.6547-6554.1992. View

Shioda T, Levy J, Cheng-Mayer C . Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1992; 89(20):9434-8. PMC: 50146. DOI: 10.1073/pnas.89.20.9434. View

McNearney T, Hornickova Z, Markham R, Birdwell A, Arens M, Saah A . Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci U S A. 1992; 89(21):10247-51. PMC: 50315. DOI: 10.1073/pnas.89.21.10247. View

Gorny M, Xu J, Karwowska S, Buchbinder A, Zolla-Pazner S . Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol. 1993; 150(2):635-43. View

Orloff S, Kennedy M, Belperron A, Maddon P, McDougal J . Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4. J Virol. 1993; 67(3):1461-71. PMC: 237516. DOI: 10.1128/JVI.67.3.1461-1471.1993. View

Schulz T, REEVES J, Hoad J, Tailor C, Stephens P, Clements G . Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage. AIDS Res Hum Retroviruses. 1993; 9(2):159-66. DOI: 10.1089/aid.1993.9.159. View

Levy J . Pathogenesis of human immunodeficiency virus infection. Microbiol Rev. 1993; 57(1):183-289. PMC: 372905. DOI: 10.1128/mr.57.1.183-289.1993. View

10.

Werner A, Levy J . Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4. J Virol. 1993; 67(5):2566-74. PMC: 237577. DOI: 10.1128/JVI.67.5.2566-2574.1993. View

11.

Weiss R . How does HIV cause AIDS?. Science. 1993; 260(5112):1273-9. DOI: 10.1126/science.8493571. View

12.

Hoffman A, Banapour B, Levy J . Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology. 1985; 147(2):326-35. DOI: 10.1016/0042-6822(85)90135-7. View

13.

Asjo B, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo E . Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. 1986; 2(8508):660-2. View

14.

Cheng-Mayer C, Seto D, Tateno M, Levy J . Biologic features of HIV-1 that correlate with virulence in the host. Science. 1988; 240(4848):80-2. DOI: 10.1126/science.2832945. View

15.

Rusche J, Javaherian K, McDanal C, Petro J, Lynn D, Grimaila R . Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A. 1988; 85(9):3198-202. PMC: 280171. DOI: 10.1073/pnas.85.9.3198. View

16.

Tersmette M, Gruters R, de Wolf F, de Goede R, Lange J, Schellekens P . Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol. 1989; 63(5):2118-25. PMC: 250628. DOI: 10.1128/JVI.63.5.2118-2125.1989. View

17.

Brodsky M, Warton M, Myers R, Littman D . Analysis of the site in CD4 that binds to the HIV envelope glycoprotein. J Immunol. 1990; 144(8):3078-86. View

18.

Cheng-Mayer C, Quiroga M, Tung J, Dina D, Levy J . Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol. 1990; 64(9):4390-8. PMC: 247907. DOI: 10.1128/JVI.64.9.4390-4398.1990. View

19.

Collman R, Godfrey B, Cutilli J, Rhodes A, Hassan N, Sweet R . Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol. 1990; 64(9):4468-76. PMC: 247917. DOI: 10.1128/JVI.64.9.4468-4476.1990. View

20.

Daar E, Li X, Moudgil T, Ho D . High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1990; 87(17):6574-8. PMC: 54579. DOI: 10.1073/pnas.87.17.6574. View